[{"id":"38aae3c4-f386-4a60-a95e-c6b46ee44656","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656248","created_at":"2022-12-19T14:58:46.031Z","updated_at":"2025-02-25T14:41:44.924Z","phase":"Phase 2","brief_title":"Study of CPX-351 (VYXEOS) in Individuals \u003c 22 Years With Secondary Myeloid Neoplasms","source_id_and_acronym":"NCT05656248","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26","pipe":"","alterations":" ","tags":["TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-14"},{"id":"99225106-dfaa-4574-8f8a-c62a8252d206","acronym":"","url":"https://clinicaltrials.gov/study/NCT04293562","created_at":"2021-01-18T20:50:03.431Z","updated_at":"2025-02-25T15:11:29.634Z","phase":"Phase 3","brief_title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","source_id_and_acronym":"NCT04293562","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1186","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"e5e2b950-7554-4958-b2db-713f66c51761","acronym":"","url":"https://clinicaltrials.gov/study/NCT03280030","created_at":"2021-01-18T16:11:51.281Z","updated_at":"2025-02-25T15:42:59.213Z","phase":"Phase 2","brief_title":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","source_id_and_acronym":"NCT03280030","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/06/2018","start_date":" 04/06/2018","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 11/14/2022","study_completion_date":" 11/14/2022","last_update_posted":"2025-02-11"},{"id":"5a8a1ba9-7750-4d42-886f-26c4d198762e","acronym":"NCI-2018-01812","url":"https://clinicaltrials.gov/study/NCT03672539","created_at":"2021-01-18T18:00:52.647Z","updated_at":"2025-02-25T15:43:12.491Z","phase":"Phase 2","brief_title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03672539 - NCI-2018-01812","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-10"},{"id":"5adabdf3-1484-4c8e-ac66-a9230e113fb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04915612","created_at":"2021-06-07T15:53:27.598Z","updated_at":"2025-02-25T15:35:05.555Z","phase":"Phase 1","brief_title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04915612","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-10"},{"id":"d48274bb-de2d-4319-b258-4def71b8a13e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05558124","created_at":"2022-09-28T14:56:07.027Z","updated_at":"2025-02-25T16:33:08.602Z","phase":"Phase 1","brief_title":"CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML","source_id_and_acronym":"NCT05558124","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/16/2023","start_date":" 02/16/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-07"},{"id":"ee309a82-4f0b-426f-a0b1-deeeabf2fd59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802161","created_at":"2021-03-17T15:57:34.517Z","updated_at":"2025-02-25T16:32:23.537Z","phase":"Phase 2","brief_title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","source_id_and_acronym":"NCT04802161","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2","pipe":" | ","alterations":" Chr del(11q)","tags":["RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"96a46201-6c05-499a-b5e8-480c4ba52158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382158","created_at":"2021-01-18T16:41:19.886Z","updated_at":"2025-02-25T17:29:36.962Z","phase":"","brief_title":"International PPB/DICER1 Registry","source_id_and_acronym":"NCT03382158","lead_sponsor":"Children's Hospitals and Clinics of Minnesota","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 3400","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 12/06/2030","primary_completion_date":" 12/06/2030","study_txt":" Completion: 12/06/2035","study_completion_date":" 12/06/2035","last_update_posted":"2025-01-30"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"7d7a1304-f3ad-4177-9429-c404e09df0b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06703593","created_at":"2025-02-26T11:48:22.442Z","updated_at":"2025-02-26T11:48:22.442Z","phase":"Phase 2","brief_title":"Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients","source_id_and_acronym":"NCT06703593","lead_sponsor":"British University In Egypt","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-11-25"},{"id":"411c6656-9452-41f8-a0dc-a43d6083250d","acronym":"KEYNOTE-A91","url":"https://clinicaltrials.gov/study/NCT04701476","created_at":"2021-01-19T20:50:41.794Z","updated_at":"2025-02-25T16:11:01.325Z","phase":"Phase 2","brief_title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","source_id_and_acronym":"NCT04701476 - KEYNOTE-A91","lead_sponsor":"Teclison Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Tirazone (tirapazamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-22"},{"id":"ee828508-f89b-44a7-a9da-155aa80b2469","acronym":"","url":"https://clinicaltrials.gov/study/NCT06520163","created_at":"2025-02-27T07:53:35.947Z","updated_at":"2025-02-27T07:53:35.947Z","phase":"Phase 3","brief_title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","source_id_and_acronym":"NCT06520163","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-25"},{"id":"55079916-4788-41a0-a5ca-a4084d122a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024552","created_at":"2021-08-27T12:52:57.710Z","updated_at":"2024-07-02T16:34:26.210Z","phase":"Phase 1","brief_title":"Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML","source_id_and_acronym":"NCT05024552","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-13"},{"id":"88697519-a0e5-4dd6-90f5-d7ce8a3d445d","acronym":"RAPID","url":"https://clinicaltrials.gov/study/NCT00268853","created_at":"2021-07-05T15:58:28.279Z","updated_at":"2024-07-02T16:35:00.098Z","phase":"Phase 2","brief_title":"A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","source_id_and_acronym":"NCT00268853 - RAPID","lead_sponsor":"CTI BioPharma","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Pixuvri (pixantrone)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2024-05-30"},{"id":"5c7bafb8-a49c-4d34-97a5-3ed538c792ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832320","created_at":"2023-04-27T14:04:55.563Z","updated_at":"2024-07-02T16:35:04.431Z","phase":"","brief_title":"Optimum Induction Therapy of Low-risk APL","source_id_and_acronym":"NCT05832320","lead_sponsor":"Peking University People's Hospital","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"737bf8ac-224d-4890-9289-ef1407053b41","acronym":"VITAL","url":"https://clinicaltrials.gov/study/NCT02658487","created_at":"2021-01-18T12:56:58.878Z","updated_at":"2024-07-02T16:35:06.085Z","phase":"Phase 2","brief_title":"Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT02658487 - VITAL","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SRC","pipe":"","alterations":" ","tags":["SRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-03"},{"id":"3b52b9d4-20d4-4a79-a816-f21eb9b91b3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807932","created_at":"2023-04-11T14:03:36.196Z","updated_at":"2024-07-02T16:35:06.548Z","phase":"Phase 1/2","brief_title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","source_id_and_acronym":"NCT05807932","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation","tags":["KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • fludarabine IV • Grafapex (treosulfan) • Amsidine (amsacrine)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/30/2028","study_completion_date":" 01/30/2028","last_update_posted":"2024-05-01"},{"id":"ca2289fb-f2cb-4b25-b323-4166bdc02859","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610735","created_at":"2022-11-09T13:56:41.133Z","updated_at":"2024-07-02T16:35:07.823Z","phase":"Phase 1/2","brief_title":"Combination Therapy for Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05610735","lead_sponsor":"Sham Sunder Kakar","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-04-24"},{"id":"1903d6da-d5c7-43b4-a343-51787a604398","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070564","created_at":"2021-01-18T00:10:47.683Z","updated_at":"2024-07-02T16:35:09.760Z","phase":"Phase 3","brief_title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT00070564","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3294","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-15"},{"id":"033a25e7-931d-47a6-b298-aba5aa713490","acronym":"","url":"https://clinicaltrials.gov/study/NCT06313047","created_at":"2024-03-16T00:37:11.773Z","updated_at":"2024-07-02T16:35:12.371Z","phase":"","brief_title":"Pharmacogenetic of Doxorubicin in HCC.","source_id_and_acronym":"NCT06313047","lead_sponsor":"Rehab Werida","biomarkers":" GSTP1","pipe":"","alterations":" ","tags":["GSTP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2024-03-28"},{"id":"282de3d0-8f82-4895-a112-bc0353a05ae5","acronym":"NSABP B-30","url":"https://clinicaltrials.gov/study/NCT00003782","created_at":"2021-01-17T22:53:06.131Z","updated_at":"2024-07-02T16:35:13.405Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","source_id_and_acronym":"NCT00003782 - NSABP B-30","lead_sponsor":"NSABP Foundation Inc","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 5351","initiation":"Initiation: 03/01/1999","start_date":" 03/01/1999","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2024-03-21"},{"id":"b231ea21-7f7f-446d-8bf7-574330cb0835","acronym":"","url":"https://clinicaltrials.gov/study/NCT05536154","created_at":"2022-09-10T11:56:36.792Z","updated_at":"2024-07-02T16:35:14.036Z","phase":"","brief_title":"Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies","source_id_and_acronym":"NCT05536154","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-19"},{"id":"6053286c-83b6-47bb-9279-55103c8270d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493164","created_at":"2021-01-18T21:35:03.148Z","updated_at":"2024-07-02T16:35:14.734Z","phase":"Phase 2","brief_title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT04493164","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"522c49af-78dd-4744-a59b-263e97c777c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05019716","created_at":"2021-08-25T14:53:05.366Z","updated_at":"2024-07-02T16:35:16.121Z","phase":"Phase 1/2","brief_title":"Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","source_id_and_acronym":"NCT05019716","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"}]